A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
Primary Purpose
Open-Angle Glaucoma
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Anecortave Acetate
Anecortave Acetate
Anecortave Acetate
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Open-Angle Glaucoma focused on measuring Open-Angle Glaucoma, Intraocular Pressure, Anecortave Acetate
Eligibility Criteria
Inclusion Criteria:
- Patients at least 18 years old with a clinical diagnosis of Open-Angle Glaucoma for at least 6 months and currently treated with a monotherapy hypotensive medication
Exclusion Criteria:
- Prior angle surgery in the study eye, severe visual field loss in either eye, and any other form of glaucoma besides open-angle glaucoma
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Arm Label
1
2
3
4
Arm Description
Placebo treatment with vehicle
Low dose of study medication
Middle dose of study medication
High dose of study medication
Outcomes
Primary Outcome Measures
Mean Intraocular Pressure
Secondary Outcome Measures
Percent of patients with therapeutic benefit, number and percent of treatment failure and time to treatment failure
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00705770
Brief Title
A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
Study Type
Interventional
2. Study Status
Record Verification Date
July 2008
Overall Recruitment Status
Withdrawn
Why Stopped
Change in study design
Study Start Date
May 2008 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
July 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether Anecortave Acetate is effective for lowering intraocular pressure caused by open-angle glaucoma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open-Angle Glaucoma
Keywords
Open-Angle Glaucoma, Intraocular Pressure, Anecortave Acetate
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Placebo treatment with vehicle
Arm Title
2
Arm Type
Experimental
Arm Description
Low dose of study medication
Arm Title
3
Arm Type
Experimental
Arm Description
Middle dose of study medication
Arm Title
4
Arm Type
Experimental
Arm Description
High dose of study medication
Intervention Type
Drug
Intervention Name(s)
Anecortave Acetate
Intervention Description
Low dose
Sustained release depot suspension
Intervention Type
Drug
Intervention Name(s)
Anecortave Acetate
Intervention Description
Middle dose
Sustained release depot suspension
Intervention Type
Drug
Intervention Name(s)
Anecortave Acetate
Intervention Description
High dose
Sustained release depot suspension
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo treatment with vehicle
Primary Outcome Measure Information:
Title
Mean Intraocular Pressure
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Percent of patients with therapeutic benefit, number and percent of treatment failure and time to treatment failure
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients at least 18 years old with a clinical diagnosis of Open-Angle Glaucoma for at least 6 months and currently treated with a monotherapy hypotensive medication
Exclusion Criteria:
Prior angle surgery in the study eye, severe visual field loss in either eye, and any other form of glaucoma besides open-angle glaucoma
12. IPD Sharing Statement
Learn more about this trial
A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
We'll reach out to this number within 24 hrs